ASP8273

DRUG2 trials

Sponsors

Astellas Pharma Inc, Astellas Pharma Global Development, Inc.

Conditions

Non-small Cell Lung CancerSubjects With NSCLC With an EGFR Activating Mutation

Phase 1

An Open Study of ASP8273 in Patients With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

TerminatedNCT02192697

Astellas Pharma IncNon-small Cell Lung Cancer

Start: 2014-01-23End: 2017-06-14Updated: 2024-11-14

Phase 2

A Study for Subjects Who Are Participating in an Astellas-sponsored ASP8273 Study

WithdrawnNCT03042013

Astellas Pharma Global Development, Inc.Subjects With NSCLC With an EGFR Activating Mutation

Start: 2017-02-28End: 2017-02-28Updated: 2017-07-11

Related Papers

Clinical activity of ASP8273 in Asian patients with non-small-cell lung cancer with EGFR activating and T790M mutations.

2018-08-0911 citations

<scp>ASP</scp>8273 tolerability and antitumor activity in tyrosine kinase inhibitor‐naïve Japanese patients with <i><scp>EGFR</scp></i> mutation‐positive non‐small‐cell lung cancer

Cancer Science2018-05-2835 citations

Abstract B188: Preclinical antitumor activity of ASP8273, a mutant-selective irreversible EGFR inhibitor in an AXL-overexpressing NSCLC model

Molecular Cancer Therapeutics2015-12-011 citations

Abstract 2586: ASP8273 selectively inhibits mutant EGFR signal pathway and induces tumor shrinkage in EGFR mutated tumor models

Cancer Research2015-08-019 citations

ASP8273, a mutant-selective irreversible EGFR inhibitor in patients (pts) with NSCLC harboring EGFR activating mutations: Preliminary results of first-in-human phase I study in Japan.

Journal of Clinical Oncology2015-05-2026 citations